We offer a substantial discount on larger orders,
please inquire via email@example.com
or Fax: 1-201-884-1288 (USA Fax#)
We match the lowest price on market.
The effect of AZD0530, a dually active inhibitor of c-Src and Bcr-ABL, on bone resorption, has been tested in a Phase I clinical trials with promising results.A phase II trial of AZD0530, an oral Src-family kinase inhibitor, in patients with advanced castration resistant prostate cancer was conducted. The primary endpoint was prostate cancer-specific antigen (PSA) response rate, defined as a 30% or greater decrease. AZD0530 inhibited tumor growth in a manner independent of dose and inhibited phosphorylation of Focal adhesion kinase (FAK) and paxillin in a dose-dependent manner in a Calu-6 xenograft model.